Antibiotic resistance in gonorrhea Antibiotic resistance in gonorrhea The Gonorrhea bacterium Neisseria gonorrhoeae has developed antibiotic resistance to many antibiotics. The bacteria was first identified in 1879, although some Biblical scholars believe that references to the disease can be found as early as Parshat Metzora of the Old Testament. In the 1940s effective treatment with penicillin became available, but by the 1970s resistant strains predominated. Resistance to penicillin has developed through two mechanisms: chromasomally mediated resistance (CMRNG) and penicillinase-mediated resistance (PPNG). CMRNG involves step wise mutation of penA, which codes for the penicillin-binding protein (PBP-2); mtr, which encodes an efflux pump that removes penicillin
Antibiotic properties of nanoparticles enhanced or induced with the addition of organic drugs. Gold particles, while not inherently antimicrobial, were discovered to express antimicrobial properties when functionalized with ampicillin. In addition to this, gold nanoparticles demonstrated improved membrane permeability with the addition of 4,6-diamino-2-pyrimidenthiol (DAPT) and non-antiobiotic amines (NAA) to their surfaces. Antibiotic properties of nanoparticles Nanoparticles have been studied extensively for their antimicrobial properties in order to fight super bug bacteria. Several characteristics in particular make nanoparticles strong candidates as a traditional antibiotic drug alternative. Firstly, they have a high surface area to volume ratio, which increases contact area with target organisms. Secondly,